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 ❚ ABSTRACT
Objective: To evaluate the psychometric properties of the seven theoretical models proposed 
in the literature for European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30), when applied to a sample of Brazilian cancer patients. 
Methods: Content and construct validity (factorial, convergent, discriminant) were estimated. 
Confirmatory factor analysis was performed. Convergent validity was analyzed using the average 
variance extracted. Discriminant validity was analyzed using correlational analysis. Internal 
consistency and composite reliability were used to assess the reliability of instrument. Results: 
A total of 1,020 cancer patients participated. The mean age was 53.3±13.0 years, and 62% 
were female. All models showed adequate factorial validity for the study sample. Convergent 
and discriminant validities and the reliability were compromised in all of the models for all of the 
single items referring to symptoms, as well as for the “physical function” and “cognitive function” 
factors. Conclusion: All theoretical models assessed in this study presented adequate factorial 
validity when applied to Brazilian cancer patients. The choice of the best model for use in research 
and/or clinical protocols should be centered on the purpose and underlying theory of each model.
Keywords: Quality of life; Neoplasms; Validation studies; Psychometrics
 ❚ RESUMO
Objetivo: Avaliar as propriedades psicométricas dos sete modelos teóricos propostos na literatura 
para o European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Core 30 (EORTC QLQ-C30), quando aplicados em uma amostra de pacientes brasileiros com câncer. 
Métodos: As validades de conteúdo e de construto (fatorial, convergente, discriminante) foram 
avaliadas. Foi realizada análise fatorial confirmatória. A validade convergente foi avaliada pela 
variância média extraída. A validade discriminante foi analisada por meio de análise correlacional. 
A consistência interna e a confiabilidade composta foram utilizadas para avaliar a confiabilidade do 
instrumento. Resultados: Participaram do estudo 1.020 pacientes com câncer. A média de idade 
foi 53,3±13,0 anos, e 62% eram do sexo feminino. Todos os modelos mostraram validade fatorial 
adequada para a amostra de estudo. As validades convergente e discriminante e a confiabilidade 
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In the literature, there are currently seven proposals 
for theoretical models that can be used to interpret the 
EORTC QLQ-C30. These proposals were tested by 
Gundy et al.,(18) on a sample obtained from a database 
including 48 countries. The first proposal is based on a 
standard model composed of nine first-order factors and 
five single terms, grouped together into a factor referred 
to as “spurious”. The second and third proposals are 
aligned with models composed of nine first-order 
factors and two second-order factors (“physical health” 
and “mental health”). The fourth proposal also has 
nine first-order factors and two second-order factors; 
however, the second-order factors in this proposal are 
referred to as “burden symptom” and “function”. In 
the fifth proposal, these two second-order factors are 
combined into a single factor known as “health-related 
quality of life”. These five models are reflective and 
oblique. The last two proposals are formative (causal) 
models, one with and one without path analysis. The 
authors concluded that all proposals had adequate 
validity for the sample; however, they pointed out 
the formative models were slightly inferior to that of 
other models.
Despite the extensive use of the EORTC QLQ-C30 
in studies around the world, and the existence of 
theoretical model proposals for the questionnaire, 
no studies on Brazilian samples that assessed metric 
properties of the questionnaire were found in the 
literature, nor were any studies that tested all seven 
theoretical models presented in the literature. 
 ❚ OBJECTIVE
To assess the psychometric properties of the theoretical 
models proposed in the literature for the EORTC 
QLQ-C30 when applied to a sample of Brazilian cancer 
patients. 
 ❚ METHODS
Sampling and study design
A cross-sectional study with a non-probabilistic sampling 
design was used. In this study, a total of 1,099 cancer 
patients receiving treatment at the Hospital de Câncer 
de Barretos, in the State of São Paulo, Brazil, were 
invited to participate.
The minimum sample size was calculated based 
on the recommendations by Hair Jr. et al.,(19) who 
suggested the need for five to ten subjects for each 
model parameter. In addition, in the theoretical 
proposals of the EORTC QLQ-C30 presented by Gundy 
et al.,(18) the maximum number of parameters was 41. 
foram comprometidas em todos os modelos para todos os itens 
isolados referentes aos sintomas, bem como para os fatores “função 
física” e “função cognitiva”. Conclusão: Todos os modelos teóricos 
avaliados neste estudo apresentaram validade fatorial adequada 
para pacientes brasileiros com câncer. A escolha do melhor modelo 
para uso em pesquisa e/ou protocolos clínicos deve ser baseada na 
finalidade e na teoria subjacente de cada modelo.
Descritores: Qualidade de vida; Neoplasias; Estudos de validação; 
Psicometria
 ❚ INTRODUCTION
As diagnostic techniques and treatments evolve and 
become more modern in the field of oncology, patients 
have longer survival. Therefore, it is necessary to 
understand patients’ quality of life.(1,2) In clinical practice, 
the results of this investigation can be relevant to guide 
physicians and interdisciplinary teams in decision-
making, by implementing treatment protocols. 
Estimating quality of life is a complex task. It can 
be measured using several dimensions, such as patient’s 
health, functional capacity, symptoms, psychosocial 
well-being, and life satisfaction.(3) In an attempt to 
minimize bias and/or difficulty in interpreting results 
of this estimate, different theories and instruments 
have been developed to address the concept of quality 
of life. Each focuses on different aspects inherent to 
this construct.
Specifically for cancer patients, some studies focused 
on aspects related to health, disease and treatment.(3,4) 
One of the instruments most often used in this 
investigation is the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire 
Core 30 (EORTC QLQ-C30), created as an initiative 
of the Quality of Life Group, from the EORTC.(5) The 
EORTC QLQ-C30 is currently on its third version. It 
was originally developed in Belgium, and it is currently 
available in many country-specific versions, including 
United States,(6) Turkey,(7) Germany,(8) Singapore,(9) 
Thailand,(10) Spain,(11) China,(12) Indonesia,(13) Mexico,(14) 
Lebanon,(15) Brazil(16) and Morocco.(17) 
The instrument is composed of 30 items, divided 
into five functioning scales (physical, role, cognitive, 
emotional, and social), three symptom scales (fatigue, 
pain, nausea and vomiting), one scale that evaluates 
overall quality of life, five single terms (dyspnea, sleep 
disturbance, appetite loss, constipation, and diarrhea), 
and one separate item to evaluate financial impact.(5) 
Responses are given on a 4-point Likert scale, except 
for the items that evaluate overall quality of life (items 
29 and 30), which are given on a 7-point Likert scale.
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Therefore, the minimum sample size was between 205 
and 410 individuals. Since stability of the instrument 
in independent samples was also tested in the current 
study, the use of a second sample of the same size 
was necessary. In light of the lack of Brazilian studies 
assessing the psychometric qualities of the EORTC 
QLQ-C30 on Brazilian cancer patient populations, we 
decided to use a large enough sample to conveniently 
capture population variability.(20)
The following exclusion criteria were adopted: patients 
who had undergone medium- or large-scale surgeries, 
patients with cognitive deficits, patients receiving 
palliative care, patients with severe psychiatric disorders, 
and patients aged under 18 years. 
To characterize the sample, clinical and demographic 
data on the patients were collected. The demographic 
characteristics included sex, age, socioeconomic class, 
and schooling level of the head of household. Age 
was measured as years completed, and socioeconomic 
class and schooling levels were classified according 
to the Brazilian Economic Classification Criteria.(21) 
The clinical data considered at the outpatients clinic 
were presence of a defined diagnosis (yes/no), time 
interval since diagnosis (in months), type of cancer 
(classified by area and based on tumor location), 
staging of the disease (radiation therapy, chemotherapy 
associated with radiation therapy, hormone therapy, 
or immunotherapy), and the presence of metastasis 
(yes/no).
It is important to mention that not all patients 
answered all questions of the demographic inventory, 
and some clinical data were not found in some medical 
history reports.
Measurement instrument 
The impact of cancer and its treatment on quality of 
life was estimated using the third version of the EORTC 
QLQ-C30, which was proposed by the EORTC.(5) 
The original Portuguese version of EORTC QLQ-C30 
presented by the EORTC was used for data collection.
Data collection
Patients were recruited in the waiting rooms of the 
outpatient’s clinic (97.0%) and in the clinical inpatients 
unit of the hospital (3.0%). The data were collected from 
2013 to 2014 by means of personal interviews, at the 
outpatient’s clinic of the Hospital de Câncer de Barretos, 
by an interviewer who had been properly trained in a 
pilot study.
Psychometric properties
The current validity of the construct of EORTC 
QLQ-C30 was analyzed using the factorial, convergent, 
and discriminant validity. 
Factorial validity
In this study seven models (model a − Ma, model 
b − Mb, model c − Mc, model d − Md, model e − 
Me, model f − Mf, and model g − Mg) proposed for 
the EORTC QLQ-C30(18) were assessed (Table 1). All 
Table 1. Complete models evaluated of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Model Second-order factor First-order factor Items Correlated factors
a - Quality of life →29, 30 All
- Physical function →1, 2, 3, 4, 5
- Role function →6, 7
- Emotional function →21, 22, 23, 24
- Cognitive function →20, 25
- Social function →26, 27
- Fatigue →10, 12, 18
- Nausea and vomiting →14, 15
- Pain →9, 19
- Spurious →8, 11, 13, 16, 17
b - Quality of life →29, 30 Quality of life, mental health and physical health
Physical health →Physical function →1, 2, 3, 4, 5
→Nausea and vomiting →14, 15
- →11, 13, 16, 17
Mental health →Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
Both factors (mental health and physical health) →Social function →26, 27
continue...
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Table 1. Complete models evaluated of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Model Second-order factor First-order factor Items Correlated factors
→Fatigue →10, 12, 18
→Role function →6, 7
→Pain →9, 19
- →8
b adapted - Quality of life →29, 30 Quality of life, mental health and physical health
Physical health →Physical function →1, 2, 3, 4, 5
→Nausea and vomiting →14, 15
→Role function →6, 7
→Fatigue →10, 12, 18
→Pain →9, 19
- →8, 11, 13, 16, 17
Mental health →Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
→Social function →26, 27
→Pain →9, 19
- →8
c - Quality of life →29, 30 Quality of life, mental function and physical burden
Physical burden →Physical function →1, 2, 3, 4, 5
→Fatigue →10, 12, 18
→Nausea and vomiting →14, 15
→Pain →9, 19
- →8, 11, 13, 16, 17
Mental function →Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
Both factors (mental function and physical burden) →Role function →6, 7
→Social function →26, 27
c adapted - Quality of life →29, 30 Quality of life, mental function and physical burden
Physical burden →Physical function →1, 2, 3, 4, 5
→Fatigue →10, 12, 18
→Nausea and vomiting →14, 15
→Pain →9,19
- →8, 11, 13, 16, 17
→Role function →6, 7
Mental function →Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
→Social function →26, 27
d - Quality of life →29, 30 Quality of life, function and burden
Function →Physical function →1, 2, 3, 4, 5
→Role function →6, 7
→Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
→Social function →26, 27
Burden →Fatigue →10, 12, 18
→Nausea and Vomiting →14, 15
→Pain →9, 19
- →8, 11, 13, 16, 17
e - Quality of life →29, 30 Quality of life and health-related quality of life
Health-related quality of life →Physical function →1, 2, 3, 4, 5
→Role function →6, 7
→Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
→Social function →26, 27
→Fatigue →10, 12, 18
continue...
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Table 1. Complete models evaluated of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Model Second-order factor First-order factor Items Correlated factors
→Nausea and Vomiting →14, 15
→Pain →9, 19
- →8, 11, 13, 16, 17
f* and g† Quality of life →29, 30 None
Function →Physical function →1, 2, 3, 4, 5
→Role function →6, 7
→Emotional function →21, 22, 23, 24
→Cognitive function →20, 25
→Social function →26, 27
Burden ←Fatigue →10, 12, 18
←Nausea and vomiting →14, 15
←Pain →9, 19
- ←8, 11, 13, 16, 17
→Quality of life and function -
* formative first-order factors with freely estimated weights; † formative first-order factors with fixed weights. The arrows refer to the direction of the trajectories that must be used to build the model.
models were tested for the study sample by confirmatory 
factor analysis (CFA), using the matrix of polychoric 
correlations and the estimation method weighed 
least squares mean and variance adjusted (WLSMV) 
implemented through MPLUS 7.2 software (Muthén 
& Muthén, Los Angeles, CA, USA). The χ² ratio and 
degrees of freedom (df) were used as indexes to assess 
the quality of fit (χ2/df). In addition, the comparative 
fit index (CFI), goodness of fit index (GFI), Tucker 
Lewis index (TLI) and the root mean square error 
of approximation (RMSEA) with 90% confidence 
interval were also used.(22) The fit of the model was 
considered adequate when χ2/df ≤2.0, CFI and TLI 
≥0.90, and RMSEA ≤0.10.(22) Root mean square 
error of approximation values were used to compare 
the models; those with lower values were chosen as the 
best one.(23) 
The items that presented factor weights (λ) <0.40 
were removed from the models, like the items found 
to be redundant by the modification indices estimated 
by Lagrange multiplier method (LM >11; p<0.001). 
Modification indices were also used to check for 
correlations between item errors.(22)
Convergent validity
To assess the convergent validity of the EORTC 
QLQ-C30, the average extracted variance (AVE) was 
calculated.(24) Values of AVE ≥0.50 were considered 
adequate.(22)
Discriminant validity
Discriminant validity was estimated using correlational 
analysis between the factors, and values were considered 
adequate when AVEi and AVEj ≥rij² (square of the 
correlation between the factors).(22,24)
Reliability
Reliability was estimated using the composite reliability 
(CR)(24) and Cronbach’s α coefficient.(25) Values of CR 
and α ≥0.70 were considered adequate. 
Ethical considerations
This study was approved by the Ethics Committee for 
Human Research at the Hospital de Câncer de Barretos 
(under no. 561/2011). Only patients who agreed to and 
signed the Informed Consent Form were included in 
the study.
 ❚ RESULTS
A total of 1,020 patients (compliance rate of 92.8%) 
with defined neoplasia diagnosis participated. The 
majority were women (n=633), were interviewed in 
the ambulatory center (96.9%), and belonged to the 
socioeconomic class C (estimated monthly household 
income: R$1.147,00 to R$1.685,00. The average age of 
the participants was 53.3±13.0 years. As for the type of 
neoplasia, 31.2% of patients had breast cancer; 20.0% 
cancer of the lower digestive tract; 11.1% gynecological 
cancers; 9.6% cancer of the upper digestive tract; 7.4% 
cancers of the head and neck; 7.4% urological cancers; 
and 13.3% had other types of cancer. Most patients 
were in stage III (38.5%) of the disease, and their 
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cancers had not metastasized (61.8%). The number of 
patients in stages I and II totaled 34.0%. Chemotherapy 
was the most prevalent treatment (64.0%), followed by 
radiation therapy (17%) and chemotherapy associated 
with radiation therapy (15%). 
The information on the confirmatory factor analysis 
of the different models of the EORTC QLQ-C30 can 
be found in table 2. It should be clarified that when the 
proposed EORTC QLQ-C30 factorial structures were 
analyzed, the Mb and Mc, presented by Gundy et al.,(18) 
did not fit the sample. In order for them to be fitted 
it was necessary to remove some shared trajectories 
so that the models were modified. These models were 
called “adapted”. This adaptation was made by the 
researchers based on the theoretical approximation of 
the content of the first order factors and/or items with 
the second order factors. 
For Ma, Mb, Mc, Md, and Me, items 16 and 17 
presented inadequate factor weights and were excluded. 
The Mf and Mg showed adequate fit without changes. 
The seven factorial models tested, after refinement, 
presented adequate fit to the data. Comparatively, 
Mb presented higher RMSEA values. Convergent and 
discriminant validities have been compromised in all 
models for isolated items relating to symptoms and for 
the factors from physical and cognitive functions. The 
values found in the composite reliability and internal 
consistency showed that the models for the isolated 
items relating to symptoms and for the factor of cognitive 
function did not present adequate reliability. 
Table 2. Indicators for evaluation of psychometric properties of factor models of the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30)
Model
CFA
e AVE CR α
λ β (p<0.001) χ2/df CFI TLI RMSEA (90%CI) r2
a complete* 0.22-1.00 - 3.07 0.97 0.96 0.045 (0.042-0.049) 0.05-0.83 - 0.21-0.88 0.54-0.94 0.40-0.84
a refined† 0.45-1.00 - 3.59 0.97 0.96 0.051 (0.047-0.054) 0.05-0.83 16, 17 0.30-0.88 0.56-0.94 0.39-0.84
a refined† (without spurious factor) 0.53-1.00 - 3.99 0.97 0.96 0.055 (0.051-0.058) 0.05-0.83 - 0.55-0.88 0.66-0.94 0.40-0.84
b adapted 0.23-1.00 0.39-0.96 5.76 0.92 0.91 0.069 (0.066-0.072) 0.29-0.63 - 0.23-0.88 0.57-0.94 0.40-0.84
b adapted‡ refined† 0.48-1.00 0.39-0.97 6.60 0.92 0.91 0.075 (0.072-0.078) 0.29-0.63 16, 17 0.32-0.88 0.58-0.94 0.40-0.84
c adapted‡ 0.22-1.00 0.59-0.95 3.54 0.96 0.95 0.050 (0.047-0.053) 0.32-0.65 - 0.25-0.88 0.59-0.94 0.40-0.84
c adapted‡ refined† 0.47-1.00 0.59-0.95 4.01 0.95 0.95 0.055 (0.052-0.058) 0.32-0.64 16, 17 0.36-0.88 0.62-0.93 0.30-0.84
d 0.23-0.99 0.57-0.98 3.99 0.95 0.95 0.055 (0.052-0.058) 0.30-0.83 - 0.27-0.87 0.62-0.93 0.40-0.84
d refined† 0.48-0.99 0.58-0.99 4.54 0.95 0.94 0.059 (0.056-0.062) 0.29-0.83 16, 17 0.39-0.87 0.65-0.93 0.30-0.84
e 0.22-0.99 0.57-0.94 3.99 0.95 0.94 0.055 (0.052-0.057) 0.38 - 0.24-0.87 0.58-0.93 0.40-0.84
e refined† 0.47-1.00 0.57-0.94 4.53 0.95 0.94 0.059 (0.056-0.062) 0.38 16, 17 0.35-0.88 0.61-0.94 0.30-0.84
f 0.54-1.00 0.20-1.00 3.73 0.96 0.95 0.052 (0.049-0.055) - - 0.18-0.88 0.49-0.88 0.40-0.84
g 0.54-1.00 0.20-1.00 3.74 0.96 0.95 0.052 (0.049-0.055) - - 0.19-0.88 0.51-0.93 0.40-0.84
* original; † fitted; ‡ adapted model by authors. 
CFA: confirmatory factor analysis: λ: factor weight; χ²/df: χ² ratio by degree of freedom; CFI: comparative fit index; TLI: Tucker Lewis index; RMSEA: root mean square error of approximation; r2: square of the correlation between the factors; e: excluded 
items; AVE: average variance extracted; CR: composite reliability; α: Cronbach alpha coefficient.
 ❚ DISCUSSION
The objective of this study was to estimate, for very first 
time in the literature, the psychometric properties of 
the seven factorial models proposed for the EORTC 
QLQ-C30, when applied to a sample of Brazilian cancer 
patients. The results showed that all models proposed 
exhibited satisfactory factorial validity for the sample. 
These findings are consistent with those reported by 
Gundy et al.(18) However, for the data presented by these 
authors, the Mb was considered the most indicated. 
In our study, although this model presented adequate 
fit to the data, comparing to the other models (e.g., 
RMSEA values), this does not seem to be the model of 
choice. Given the adequacy of the models to the data, 
we suggest that the choice of the model to be used in 
clinical context and/or screening should be guided by 
the investigation objective. Thus, this choice will be 
centered in the underlying theory for the elaboration 
of each model, since that statistically all the proposals 
presented adequate factorial validity. 
Among the limitations found in the psychometric 
properties of EORTC QLQ-C30 we can highlight the 
high χ² values observed in the CFA, the low convergent 
and discriminant validity and reliability. The χ² values 
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were probably increased due to the high sensitivity 
of this index to the sample size(26) and, therefore, this 
aspect does not characterize a limitation for the factorial 
validity of the models. Regarding to the low convergent 
and discriminant validity of the isolated items, this fact 
may have occurred due to the theoretical approach 
between the contents of the same and the other factors 
of the instrument. In contrast, the low reliability 
observed may be a reflection of the reduced number 
of items per factor, and the grouping of items with low 
factorial weights in the same factor. This aspect can not 
be considered a limitation of the EORTC QLQ-30, but 
only a warning signal when used in samples with similar 
characteristics to the present study, because it can 
not replicate in samples with different characteristics 
and/or contexts.
The items 16 and 17 had to be removed so that the 
reflective models presented adequate fit to the data (Ma, 
Mb, Mc, Md, Me). These items refer to gastrointestinal 
symptoms (constipation and diarrhea), and their 
inadequacy can be attributed to the characteristics of 
the study sample, i.e., oncology outpatients. These 
symptoms in cancer patients may be less significant 
than in others, considering the impacts of disease and 
of treatment on quality of life. 
One limitation of this study was the convenience 
sampling that resulted in data of cancer patients with 
specific clinical characteristics (e.g. outpatient care, 
with breast and lower digestive tract neoplasms, non-
metastatic, and on chemotherapy), making it difficult 
to generalize the evidence presented for the population 
of oncological patients. We attempted to minimize this 
limitation by using an extended sample size. However, 
we believe that despite this limitation, this study 
presented evidence of the validity and reliability of 
different theoretical models of EORTC QLQ-C30 for 
a Brazilian sample.
This evidence may be important to assess quality of 
life of cancer patients in clinical and epidemiological 
contexts, not only regarding the choice of the 
measurement instrument but also the theoretical model 
to be used and its operation.
 ❚ CONCLUSION
All theoretical models presented in the literature for the 
EORTC QLQ-C30 exhibit satisfactory factorial validity 
when applied to Brazilian cancer patients. Convergent 
and discriminant validity and reliability are useful for 
the cognitive function factor and for the single items 
related to symptoms. 
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